Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma

Archives of Surgery

Volumn 146, Issue 6, 2011, Pages 675-681

  Chan, Albert C Y ^a   Chok, Kenneth S H ^a   Yuen, Wai Key ^a   Chan, See Ching ^a   Poon, Ronnie T P ^a   Lo, Chung Mau ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; LAMIVUDINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TEACHING HOSPITAL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; GUANINE; HEPATECTOMY; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

EID: 79959336054     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2011.125     Document Type: Article

References (26)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733- 1745. (Pubitemid 27527771)
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(5)(suppl 2):S72-S78. (Pubitemid 35278644)
3. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12(8):1295-1303.
4. Liaw YF, Sung JJ, Chow WC, et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-1531.
5. Matsumoto A, Tanaka E, Rokuhara A, et al; Inuyama Hepatitis Study Group. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res. 2005;32(3):173-184. (Pubitemid 41078655)
6. Di Marco V, Marzano A, Lampertico P, et al; Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883-891. (Pubitemid 39288121)
7. Kim JH, Park JW, Koh DW, Lee WJ, Kim CM. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. Liver Int. 2009;29(2):203-207.
8. Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22(11):1929-1935. (Pubitemid 47525069)
9. Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin α1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology. 2006;53(68):249-252.
10. Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237(4):536-543. (Pubitemid 38176435)
11. Grazi GL, Cescon M, Ravaioli M, et al. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics: evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther. 2003;17(suppl 2):119-129. (Pubitemid 36831469)
12. Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol. 2000;18(5):1094-1101. (Pubitemid 30123788)
13. Yasui M, Harada A, Torii A, Nakao A, Nonami T, Takagi H. Impaired liver function and long-term prognosis after hepatectomy for hepatocellular carcinoma. World J Surg. 1995;19(3):439-443.
14. Greene FL, Balch CM, Page DL, et al eds; American Joint Committee on Cancer. Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
15. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl. 2004;10(2)(suppl 1):S39-S45. (Pubitemid 38240099)
16. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229(3):322-330.
17. Liu CL, Fan ST, Lo CM, Tung-Ping Poon R, Wong J. Anterior approach for major right hepatic resection for large hepatocellular carcinoma. Ann Surg. 2000;232(1):25-31. (Pubitemid 30456546)
18. Kilic ZM, Kuran S, Akdogan M, et al. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis. Adv Ther. 2008;25(3):190-200.
19. Nishida T, Kobashi H, Fujioka S, et al. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol. 2008;23(5):794-803. (Pubitemid 351519425)
20. Lai CL, Shouval D, Lok AS, et al; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011-1020. (Pubitemid 43357805)
21. Chang TT, Gish RG, de Man R, et al; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-1010. (Pubitemid 43357804)
22. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005;42(2):173-179. (Pubitemid 40143462)
23. Ko S, Nakajima Y, Kanehiro H, et al. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy: result of multivariate analysis. Ann Surg. 1996;224(5):591-595. (Pubitemid 26384881)
24. Shirabe K, Takenaka K, Taketomi A, et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer. 1996;77(6):1050-1055. (Pubitemid 26080893)
25. Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997;79(4):688-694. (Pubitemid 27076334)
26. Chen CJ, Yang HI, Su J, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73. (Pubitemid 43042691)